title: Correlation between elevated intratumoral thymidine phosphorylase and prognosis of node-positive breast carcinoma undergoing adjuvant doxifluridine treatment.
abstract: We determined intratumoral thymidine phosphorylase (dThdPase) activity in 213 patients with T2N0M0 or T2N1M0 breast cancer. After surgery doxifluridine, an intermediate metabolite of capecitabine, and tamoxifen were given by mouth. According to dThdPase activity the examined patients were classified as: A, high activity group; tumors with the activity not less than the mean value and B, low activity group; tumors with activity less than the mean value. Group A had a better prognosis than group B in node-positive patients (disease-free survival, p=0.0446; overall survival, p=0.0788). Intratumoral dThdPase activity might be a useful marker for predicting responsiveness to doxifluridine treatment in the adjuvant setting.
authors.affiliation: First Department of Surgery, Hokkaido University School of Medicine, Kita-ku, Sapporo 060-8638, Japan. medicine@med.hokudai.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.forename: Y
authors.initials: Y
authors.lastname: Maeda
authors.forename: K
authors.initials: K
authors.lastname: Watanabe
authors.forename: K
authors.initials: K
authors.lastname: Taguchi
authors.forename: F
authors.initials: F
authors.lastname: Sasaki
authors.forename: S
authors.initials: S
authors.lastname: Todo
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy / Q000201:enzymology* / Q000401:mortality / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D004967:Estrogens; D005260:Female; D005467:Floxuridine / Q000494:pharmacology / Q000627:therapeutic use*; D018734:Genes, erbB-2; D006801:Humans; D015993:Life Tables; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis* / Q000037:antagonists & inhibitors; D009376:Neoplasms, Hormone-Dependent / Q000188:drug therapy / Q000201:enzymology / Q000401:mortality / Q000601:surgery; D011374:Progesterone; D011379:Prognosis; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D016019:Survival Analysis; D013939:Thymidine Phosphorylase / Q000032:analysis* / Q000037:antagonists & inhibitors
chemical_list: D000964:Antimetabolites, Antineoplastic; D004791:Enzyme Inhibitors; D004967:Estrogens; D009363:Neoplasm Proteins; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; D005467:Floxuridine; D011374:Progesterone; D013939:Thymidine Phosphorylase; C025034:doxifluridine